Ozempic Hair Loss: 2026 NYU & Penn Studies

Two studies released in the same September 2026 news cycle asked whether GLP-1 weight-loss drugs — Ozempic, Wegovy, Zepbound — can cause hair loss. Both returned a qualified yes: an NYU Langone study (Journal of Investigative Dermatology, online Sept. 3) found men with a genetic predisposition to male-pattern baldness carry a “7 percent added risk” of hair loss if they use the drugs, while a Penn Medicine study (BMJ 2026;394:e100077) linked GLP-1 use in type 2 diabetes to increased hair-loss risk — real but muted, mostly the temporary shedding type. Neither proves the drugs cause hair loss in everyone, and neither advises stopping them.

Do GLP-1 drugs cause hair loss? The short answer

For some people, yes — but the risk is modest and differs by group. Penn Medicine found adults with type 2 diabetes starting a GLP-1 had a 37% higher risk of hair loss than SGLT-2 inhibitor users and 68% higher than DPP-4 inhibitor users — relative increases on small absolute rates (about 6.5 to 6.9 per 1,000 person-years versus 3.9 to 5.0). NYU found men whose genetics already point to male-pattern hair loss carry a “7 percent added risk” with GLP-1 use. Most shedding was telogen effluvium — temporary, non-scarring loss that typically follows rapid weight loss and usually reverses. Neither study proves the drugs directly cause hair loss in all users. Related: how side effects surface in oral GLP-1 aleniglipron trial data, and how FDA-approved GLP-1s compare with unapproved wellness peptides in our peptide FAQ.

What the two 2026 studies actually found

NYU: a genetic link in men

The NYU Langone study, online Sept. 3 in the Journal of Investigative Dermatology (DOI 10.1016/j.jid.2026.07.024), used Mendelian randomization: genetic variants that raise expression of the GLP1 receptor — the target drugs like semaglutide and tirzepatide activate — stand in for drug effect and were tested against male-pattern hair loss (androgenetic alopecia) genetics. Data came from the eQTLGen consortium (31,684 people) and the Complex Traits Genetics consortium (205,327 mostly White men).

The finding: men already at genetic risk for male-pattern hair loss “have a 7 percent added risk of losing their hair if they use drugs like Ozempic, Wegovy, and Zepbound,” per the university’s release — an association that held after adjustment for hypertension, insulin resistance, and lowered testosterone. Senior author Lynn Petukhova, PhD, called it “a modest but statistically significant increase in the risk of male pattern hair loss,” “the first genetic link between GLP-1 use and an increased risk of male-pattern hair loss.”

Limits. Mendelian randomization is a genetic proxy for lifelong receptor activity, not real drug exposure — no one in the analysis took a GLP-1. The 7 percent figure comes from the university’s release; the estimate sits in the paywalled article, not yet indexed by PubMed as of Sept. 3, 2026. The analysis was men only: no comparable female-pattern genome-wide study exists. The authors say the findings “do not establish that GLP-1 receptor agonists directly cause patterned hair loss in all users, but they do suggest that genetic susceptibility may play a role in at least some cases.”

Penn: a muted but real signal in diabetes patients

The Penn Medicine study, in the BMJ (2026;394:e100077), used a target trial emulation on electronic health records: adults with type 2 diabetes who started a GLP-1 between January 2019 and September 2024, compared with similar patients starting SGLT-2 or DPP-4 inhibitors — roughly 12,000 GLP-1 initiators versus 15,221 SGLT-2 and 11,238 DPP-4 initiators.

Over up to five years of follow-up, GLP-1 use was associated with an adjusted hazard ratio of 1.37 (95% CI 1.08 to 1.73) for hair loss versus SGLT-2 inhibitors and 1.68 (95% CI 1.28 to 2.20) versus DPP-4 inhibitors. Adjusted incidence ran about 6.9 versus 5.0 and 6.5 versus 3.9 per 1,000 person-years — why Penn called the risk “real, albeit muted.” The signal was specific to non-scarring, telogen-effluvium-type alopecia (hazard ratios 1.53 and 1.72) and consistent across age and sex. Yong Chen, PhD, the senior author, called it “the first study to look at hair loss among patients taking GLP-1s at a wide, population level.”

Limits. This is an observational EHR study, not a randomized trial. Diagnostic codes miss milder cases and add no severity grading; prescriptions don’t prove adherence; residual confounding can’t be excluded, though E-values of 2.08 and 2.75 suggest robustness. The BMJ paper notes the FDA is evaluating the hair-loss signal in postmarketing data.

Why shedding happens: rapid weight loss, and maybe more

The leading explanation is the weight loss itself. “Weight loss is a known cause of hair shedding, so GLP-1 therapy likely causes hair loss because patients on the drugs lose weight,” said George Cotsarelis, MD, chair of dermatology at Penn and a study co-author. “However, there is a chance that the drug causes hair loss through a different mechanism, and that needs to be explored.”

Rapid weight loss is a classic telogen effluvium trigger: a metabolic stressor pushes many follicles into the shedding phase at once, and hair comes out a few months later. Penn’s excess risk sat almost entirely in that non-scarring type. NYU’s finding adds a second, still-unproven layer — the drug-target pathway itself might raise male-pattern risk in predisposed men. The broader question of whether GLP-1 drugs do more than suppress appetite is also central to what the Sept. 2, 2026 Nature mouse study on semaglutide and lifespan found: late-life treatment extended life in older female mice and tempered aging hallmarks, with effects the researchers said go beyond calorie restriction — animal data, not human proof. For realistic weight-loss context, see our analysis of GLP-1 belly-fat and visceral-fat trial data. The same beyond-appetite question reaches respiratory medicine too: a UK records analysis presented at the ERS respiratory congress associated semaglutide with fewer asthma attacks and COPD flare-ups, observational and not peer-reviewed — see semaglutide and asthma/COPD at ERS 2026.

Who is most affected?

Men with a genetic predisposition. The clearest risk group is men whose genetics already point to androgenetic alopecia: in NYU’s analysis they carried the 7 percent added risk, even after adjustment for hypertension, insulin resistance, and lowered testosterone. It is patterned risk layered on risk they already carry.

People with type 2 diabetes starting a GLP-1. Penn’s cohort — the population for which drugs like Ozempic are FDA-approved — showed the elevated hazard ratios (1.37 to 1.68) with low absolute numbers and predominantly temporary shedding.

Women. Genetically, it has not been studied — and saying so plainly is part of the finding. NYU could not examine women because no female-pattern GWAS exists; Penn found its signal consistent across age and sex. Rapid weight loss can trigger temporary shedding in anyone, but whether women share the specific genetic risk NYU found in men is unknown. No 2026 study answers it, and none should be read as if it did.

Is the hair loss permanent? Recovery and what to watch

The evidence points to mostly temporary shedding, not permanent loss. Penn’s excess risk sat in non-scarring, telogen-effluvium-type alopecia — follicles are pushed into the shedding phase early but not destroyed, and this type typically resolves as weight loss stabilizes. Neither study measured regrowth directly, so precise timelines are unproven; claims that shedding “lasts exactly X months” overstate the data. Both teams agreed the right response is monitoring and shared decision-making — neither advises stopping a GLP-1 over shedding. For a parallel side-effect thread, see our coverage of GLP-1s and mental health, including the semaglutide psychiatric-hospitalization study. Another parallel thread is nutritional: persistent vomiting and rapid weight loss are the setting a February 2026 Clinical Nutrition review flags for thiamine (vitamin B1) deficiency, where it reported 15 cases of Wernicke encephalopathy in people taking GLP-1 medicines.

The Reddit study in the September 2026 news cycle: reported, not caused

Check the date first. Coverage circulating in September 2026 describes a University of Pennsylvania team’s analysis of 410,198 Reddit posts as a new study. It is not new. “Self-reported side effects of semaglutide and tirzepatide in online communities” was published in Nature Health on 10 April 2026 (DOI 10.1038/s44360-026-00108-y), promoted by Penn the same day, carried by ScienceDaily on 24 May 2026, and re-issued by ScienceDaily on 13 September 2026. The September coverage is a second wave of re-circulation of that April release — not a new study, and not a September publication.

What the study did

The team analyzed 410,198 Reddit posts mentioning semaglutide or tirzepatide, posted between May 2019 and June 2025, from 67,008 users who self-reported using the medications — self-reported, not clinically verified. Among those users, 43.5% described at least one side effect, rounded to “about 44%” in press coverage; the share is of that self-selected Reddit sample, not of GLP-1 patients generally. Gastrointestinal symptoms dominated the reports — the pattern the authors present as evidence their method detects a signal medicine already knows about.

The two symptom classes it flagged

Reproductive symptoms, including menstrual irregularities. Nearly 4% of the users in the sample who reported side effects described reproductive symptoms such as irregular cycles, heavy bleeding or bleeding between periods, and the study’s first author notes the share would be higher in a female-only sample. The published abstract states no percentage for this class.

Temperature-related complaints, including chills, feeling cold and hot flashes (the paper writes “hot flushes”). The authors flag the category as under-represented in current labelling and trials. The abstract gives no percentage for it either; the per-symptom figures that appear in some coverage come from news outlets rather than from the paper.

What the numbers cannot tell you

The study reports what people posted, not what the medications did. The authors describe the findings as associations rather than causation, and the sample is not representative: Reddit users are younger, more likely to be male and disproportionately based in the United States. The team presents the approach as a fast way to generate leads for further study, not a replacement for clinical trials. For those two flagged classes in full — every number with its denominator, the authors’ caveats and the dating chain — see our explainer on underreported GLP-1 side effects. Hair loss is not one of the two flagged classes — for that question the studies above are the evidence — and the same Reddit data says nothing about what happens to weight after treatment stops: see our GLP-1 belly-fat and visceral-fat evidence and semaglutide discontinuation rates. Vision loss is a separate question again, and the one currently in litigation: see the NAION GLP-1 vision-loss lawsuits.

If something feels new while you are on a GLP-1. Note when it started and how it tracks against dose changes, and raise it with the clinician who prescribed your medication rather than stopping a prescription on your own. This is not medical advice — talk to your prescriber.

Questions to ask your doctor

If you take a GLP-1 and notice hair shedding, raise these points with your prescriber or a dermatologist:

• Am I in a group the 2026 studies flagged — a man with a family history or early signs of male-pattern hair loss, or someone who lost weight quickly?
• Is my shedding likely the temporary, non-scarring type, and what signs would suggest something else?
• Should we check nutrient status, thyroid function, or ferritin before assuming the medication is the cause?
• How fast am I losing weight, and could moderating the rate reduce shedding?
• Should we continue, adjust, or pause the medication based on my situation and goals?
• At what point should I see a dermatologist?

Frequently asked questions

Does Ozempic cause hair loss?

Yes for some people, but the risk is modest and usually temporary. Penn Medicine’s 2026 study (BMJ) found GLP-1 use in type-2 diabetes was linked to a 37-68% higher relative risk of hair loss than two other drug classes — at low absolute risk. An NYU study published the same week found men with a genetic predisposition to male-pattern baldness had a “7 percent added risk” with GLP-1 drugs. Neither study proves the drugs cause hair loss in everyone, and most shedding was the temporary, non-scarring type.

Does semaglutide cause hair loss?

Semaglutide (Ozempic, Wegovy) is the most-studied GLP-1 in the 2026 research: Penn Medicine found increased but “muted” risk in diabetes patients (adjusted hazard ratios 1.37 vs SGLT-2 inhibitors and 1.68 vs DPP-4 inhibitors, low absolute risk), and NYU found a 7% added risk in men genetically prone to male-pattern hair loss. Rapid weight loss is the suspected driver in most cases; the shedding is typically temporary. This is not medical advice — talk to your prescriber.

Is GLP-1 hair loss permanent?

Usually not. The hair loss Penn Medicine identified was predominantly non-scarring (telogen-effluvium type), which occurs when rapid weight loss or stress pushes hair follicles into the shedding phase early — the follicles are not destroyed. Neither 2026 study measured regrowth directly, so timelines are not proven, but non-scarring shedding after weight loss typically resolves as weight stabilizes. If shedding continues or you see bald patches, ask a doctor or dermatologist.

Can GLP-1 drugs cause male pattern hair loss?

An NYU Langone study (Journal of Investigative Dermatology, online Sept 3 2026) found the first genetic link: men with gene variants tied to male-pattern baldness had a “7 percent added risk” of hair loss when using GLP-1 drugs such as Ozempic, Wegovy and Zepbound. The study used Mendelian randomization — a genetic proxy for the drugs’ receptor activity — so it did not observe actual drug use, and the researchers say it does not prove GLP-1s directly cause patterned hair loss in all men.

Does GLP-1 hair loss affect women?

Genetically, it has not been studied: the NYU analysis could only examine men because no comparable female-pattern hair-loss GWAS exists. Penn Medicine’s EHR study found its hair-loss signal was consistent across age and sex in people with type 2 diabetes. Women should not assume either result applies to them — and rapid weight loss can trigger temporary shedding in anyone.

Should I stop taking Ozempic or Wegovy if I notice hair loss?

Neither the NYU nor the Penn study advises stopping a GLP-1 medication. Both point to monitoring and shared decision-making: tell your prescriber what you’re seeing, ask whether your weight-loss rate or nutrition could be factors, and get a dermatologist referral if shedding is heavy or persistent. Never stop or change a prescribed medication without talking to your doctor. If you and your prescriber do decide to pause treatment, see what happens when you stop semaglutide.

Sources

1. NYU Langone Health news release, Sept. 3, 2026
2. JID: GLP1R expression and male-pattern hair loss (MR), online Sept. 3, 2026
3. BMJ 2026;394:e100077, online July 22, 2026
4. Penn Today, Sept. 2026
5. Penn Medicine newsroom, Aug. 31, 2026
6. MedicalResearch.com interview with Lynn Petukhova, PhD, Sept. 3, 2026
7. Novo Nordisk via PR Newswire: Ozempic FDA approval, Dec. 5, 2017
8. Sehgal NKR, Tronieri JS, Ungar L, Guntuku SC. Self-reported side effects of semaglutide and tirzepatide in online communities. Nature Health 2026;1(8):806-811 — published 10 April 2026; Penn promoted the study the same day.
9. ScienceDaily: AI uncovers hidden Ozempic side effects across 400,000 Reddit posts, Sept. 13, 2026 — the second re-circulation of the release ScienceDaily first carried on May 24, 2026.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.